43% of skilled American women leave the workplace after becoming mothers. Allison Robinson is CEO of The Mom Project which is committed to helping women remain active in the workforce and she discusses the company and its mission on The Final Round.
43% of skilled American women leave the workplace after becoming mothers. Allison Robinson is CEO of The Mom Project which is committed to helping women remain active in the workforce and she discusses the company and its mission on The Final Round.
Fisker stock rose in its debut Friday on the New York Stock Exchange as blank-check mergers continue to churn out electric car stocks.
How much money people have put away for retirement varies, naturally, by their age group. See how your savings stack up.
Markets are down, but not collapsing. Investors remain worried about the coronavirus, and Tuesday’s election remains up in the air. Uncertainty rules the day, exacerbated by recent market losses. Wall Street, however, expects that the bulls will start running again after next week’s results – who wins will be less important than having a result.In the meantime, market declines and low share prices make for a prime time to buy in – if you judge the bottom correctly. Do that, and the rest is just ‘buy low and sell high.’ And to that end, Wall Street’s analysts have been pointing out stocks that may have hit bottom.Using TipRanks database, we pinpointed three such stocks. Each is down significantly, but each also has a Strong Buy consensus rating and at least 30% upside potential for the coming months.Fury Gold Mines (FURY)Gold – just the precious metal asset – has grown popular during the course of 2020. The coronavirus crisis and investors’ desire for a stable store of value pushed it above $2,000 earlier this year, and one ounce of gold is still selling for over $1,800. For those who haven’t got that kind of resource, however, buying stock in gold miners may be the next best thing.Fury Gold Mines is a small-cap mining company headquartered in Toronto and focused on exploiting the vast resources of the Canadian North. With mines in British Columbia, northern Quebec, and the far-north territory of Nunavut, Fury has large gold reserves in both open pit and underground mines. World gold production dropped by 1% in the last 12 months, giving the first hint that we may be at ‘peak gold,’ and prices will soon increase further.That development would bode well for Fury, which operates at a net loss. The company formed earlier this year, as a restructure of Auryn Resources that involved a merger with Eastmain and the divestment of Peruvian mines. The result is a company that is focused on Canadian development, able to take advantage of Canada’s stable work environment.The stock saw sharp declines recently, when the new FURY ticker started trading, taking Auryn’s place in the market and keeping the older company’s trading history. The drop saw Fury shares shed 67% this month.Covering the stock for Cantor, analyst Matthew O’Keefe sees plenty of upside ahead. The analyst noted, "Based on a combined gold equivalent resource of 3.9Moz, Fury is trading $43/oz versus peers at $60/oz. We expect that, as the new management makes its mark with new drill results (towards the end of 2020 and throughout 2021) and demonstrates advancement of its projects, the stock should move up."But how much up? O’Keefe’s $2.60 price target on FURY suggests a 126% upside potential for the coming year and supports his Buy rating. (To watch O’Keefe’s track record, click here)The Wall Street analyst consensus on Fury is a Strong Buy, based on 4 Buy ratings with no Sells or Holds. The stock is selling for $1.13 and its $3.37 average price target suggests it has room to nearly double in the next 12 months. (See FURY stock analysis on TipRanks)Star Bulk Carries (SBLK)Next up, Star Bulk Carries, is a Greece-based shipping company specializing in the dry bulk ocean carry trade, the backbone of the world’s shipping industry. Star Bulk operates a fleet of 116 carriers, ranging in size from ~50,000 tons to giant Newcastlemax bulk haulers rated over 200,000 tons. The trade disruptions caused by corona were hard on the industry, and SBLK was no exception. The stock is down 47% year-to-date. However, the company’s financial performance this year has been in line with its historical pattern – the first half of a calendar year sees a net loss, while the second half sees net gains. The losses in 1H20 where normal for SBLK’s pattern – and the outlook for Q3 is a return to net profits, with EPS projected at 30 cents.Covering this stock for Deutsche Bank, analyst Amit Mehrotra notes a series of related points: “[We] think the company’s net debt position should improve by about $50M vs. 2Q levels, reflecting cash flow generation in excess of >$40M of debt paydown in 3Q. We also expect the company’s prospective breakeven to reduce to under $11k per day… While we remain frustrated by the lackluster performance of SBLK shares in the context of above-mentioned improving fundamentals...we remain very comfortable that the intrinsic value of SBLK’s equity value is improving in the current environment…” Mehrotra sums up his view of Star Bulk succinctly: “On the whole, we’re encouraged by the fundamental trajectory of the company…” The analyst rates SBLK a Buy, while his $15 price target implies an upside potential of 143% from current levels. (To watch Mehrotra’s track record, click here)With 3 recent Buy reviews, SBLK holds a unanimous Strong Buy rating from the analyst consensus. The stock is currently trading at $6.18 and has an average price target of $12.09, making the one-year upside 96%. (See SBLK stock analysis on TipRanks)Heritage-Crystal Clean (HCCI)Pollution is a problem, no matter what. We all want a clean environment to live in, and we should all care about how modern industrial pollutants are disposed of. Heritage-Crystal Clean inhabits that clean-up niche, providing environmental cleaning services, including vacuum services for street cleaning, light industrial and mechanical parts cleaning technology, and a variety of waste recovery services including recovery and disposal of oil and oil products, antifreezes, and general industrial liquid waste. It’s an important, often overlooked, and vital niche in a modern technological society.After a dip into negative territory in Q2, HCCI reported stronger results for Q3. Revenues gained sequentially from $74 million to $82 million, and EPS swung from a 31-cent loss to an 18-cent gain. Despite the positive results, both earnings and revenues remain depressed compared to the year-ago quarter, and the stock has failed to regain traction after last March’s decline. HCCI is down 49% year-to-date.Roth Capital’s Gerry Sweeney, in his comments on this stock, notes that “Revenue continues to rebound as economic activity improves from COVID shelter in place orders... The highlight in the quarter was a faster than anticipated rebound in margins. While margins are still down from last year’s pre-pandemic level of 25.7%, they are up from 2Q margins of (28.2%). The improvement was driven by higher labor utilization and leverage of assets, lower solvent costs, and the internalization of waste disposal…”Sweeney rates the stock a Buy. His $21 price target indicates confidence in a solid 32% upside for the next year. (To watch Sweeney’s track record, click here.)Over the past three months, three other analysts have thrown the hat in with a view on HCCI. The three additional Buy ratings provide the stock with a Strong Buy consensus rating. With an average price target of $20.75, investors stand to take home a 30% gain, should the target be met over the next 12 months. (See HCCI stock analysis at TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
“It’s hard to argue that the country doesn’t have infrastructure problems,” says Scott Davis, CEO of Melius Research. Well, there’s a giant need for greater and more accurate coronavirus testing and tracing capabilities—and that will help the companies that supply them. (ABT)’ (ticker: ABT) six coronavirus tests drove a 39% gain in third-quarter diagnostic sales.
The Dow Jones fell to its worst month since March amid a sell-off. Uncertainty over the presidential election between Donald Trump and Joe Biden looms large.
Visa Inc. and Mastercard Inc. are often viewed as one and the same in the investment community, but the small differences between their businesses are coming into focus as the COVID-19 alters the way people spend their money.
(Bloomberg) -- When talking about the biggest company in the world, it’s not unusual for there to be eye-popping numbers. But Apple Inc.’s latest superlative is not one investors would like to see.Since becoming the first American company to surpass $2 trillion in market value in August and peaking last month, the iPhone maker has lost $450 billion, wiped out by a 19% slump. The latest bout of selling -- a 5.6% drop on Friday -- took out more than $120 billion alone. Apple’s now worth $1.85 trillion and still the most valuable U.S. company, but the amount shaved from its ledger since its September peak is more than the entire market cap of Visa Inc., the seventh largest member of the S&P 500, and greater than the value of Thailand’s stock exchange.The drawdown comes as the tech giant reported iPhone sales that missed analysts’ estimates and gave no forecast for the holiday quarter. Fiscal fourth-quarter revenue from the iPhone was $26.4 billion, compared to expectations of $27.1 billion.The Nasdaq 100 Index plunged 2.6% on Friday and had its worst week since the coronavirus-induced selloff in March. Disappointing sales forecasts from tech companies like Apple, Twitter Inc. and Facebook Inc. are sparking worries about further growth potential in the names that led this year’s rebound.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
October somewhat lived up to its name as a "jinx month" for the S&P 500. But investors who found top stocks still won big gains.
Shares of United Parcel Service, Inc. (NYSE: UPS) were unaffected after the company said it was the unnamed company Fox News host Tucker Carlson called out for losing what he said is a politically sensitive package.What Happened: Carlson said during his daily "Tucker Carlson Tonight" show Wednesday that his New York office was in possession of "a collection of confidential documents related to the Biden family."Carlson was in Los Angeles at the time filming an interview with Tony Bobulinski, a former business partner of Hunter Biden, son of Democratic presidential nominee Joe Biden.Carlson asked his office to send over the documents that he described as "authentic" and potentially "damaging" to the Biden campaign. The documents were dropped off at a retail location of a "large national carrier," he said. Carlson didn't elaborate on what the documents are. Related Link: How The 2020 Presidential Election Could Impact Health Care StocksUPS Issues Statement: Carlson didn't name the company during his show. But UPS Corporate Media Relations Director Glenn Zaccara told Business Insider that UPS was the unnamed company."UPS is conducting an urgent investigation into this matter and regrets that the package was damaged," the company told Business Insider."The integrity of our network and the security of our customers' goods are of utmost importance. We will remain in frequent, direct contact with Fox News as we learn more through our investigation."To UPS' credit, Carlson said the company "went far and beyond" but "found nothing.""As of tonight, the company has no idea -- and no working theory, even -- about what happened to this trove of materials, documents that are directly relevant to the presidential campaign just six days from now," the Fox News host said.Photo by Jim.henderson via Wikimedia. See more from Benzinga * Click here for options trades from Benzinga * Molson Coors Stock Chugs Along After Big Q3 Beat * Grocery Prices A Concern As Coronavirus Cases Surge(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The ITEP data broke down the impact by state. Population has a major impact on the overall total in tax increases.
It was a busy week at Advanced Micro Devices’ (AMD) HQ. Q3 earnings, and confirmation of a $35 billion Xilinx takeover have been followed by a new product launch.On Wednesday, AMD announced the release of the first products based on its gaming optimized RDNA 2 architecture: The Radeon RX 6800, the Radeon RX 6800 XT and the Radeon RX 6900 XT, priced at $579, $649 and $999, respectively. Code named Big Navi, the desktop GPUs will hit the shelves on November 18 (RX 6800 and 6800 XT) and December 8 (RX 6900 XT).“Importantly,” said Deutsche Bank analyst Ross Seymore, “This is the first generation of AMD product in many years that, we believe, can truly be claimed to be competitive to NVDA’s highest-end gaming GPUs.”Based on Seymore’s initial impression, “all three new AMD GPUs will be within 5% of NVDA’s equivalent offerings.”In addition to performing on a similar level, the favorable pricing of both the 6800XT ($50 lower) and the 6900XT ($500 lower) to Nvidia’s equivalents, means AMD’s GPUs “present a strong competitive alternative to those at the highest end of the market.”The release is causing excitement amongst gamers and Seymore notes comparisons are being made to AMD’s 2017 and 2018 early Zen CPU launches, following which, AMD began siphoning market share away from Intel - a process that is still playing out. Does Seymore believe AMD can do the same to Nvidia? Here, the analyst “hesitates” to make such a call. Nevertheless, Seymore believes the “launch appears to be a strong step in the right direction.”“Overall,” the 5-star analyst summed up, ”We are impressed by AMD’s newest gaming GPU offerings, as they display significant improvements in efficiency and performance despite no node transition, all in slightly more than a year (typically we would’ve expected such performance increases over two years). While the lower-end pricing leaves a bit to be desired, overall we are impressed that AMD is in the same ballpark as NVDA’s latest GPUs given the significant gen-on-gen performance increase NVDA was able to achieve with their launch.”However, AMD’s hot valuation keeps Seymore on the sidelines with a Hold rating. Seymore’s $75 price target remains as well and suggests shares will stay range-bound for now. (To watch Seymore’s track record, click here)Overall, Seymore’s colleagues strike a more bullish tone. Based on 12 Buys and 6 Holds, AMD qualifies with a Moderate Buy consensus rating. The forecast is for 21% upside over the next 12 months, as indicated by the $92.71 average price target. (See AMD stock analysis on TipRanks)To find good ideas for tech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Jim Cramer shared his thoughts on the upcoming election and a potential blue wave.Cramer On The Election: "Let's see if people can fight the blue wave," Cramer said Thursday morning on CNBC. He's concerned about a potential blue wave and that "you have to be."He went on to describe a blue wave as: short and cover when the election night really ends because there's a lot of stocks in a blue wave that would be crimped by a "hijack of the far left."Cramer On A Game Plan: He went on to give a game plan for investors to make "real money.""Short the managed care stocks into a blue wave. The managed care stocks then drop 10%, then you buy the managed care stocks, leading with Centene (NYSE: CNC) and maybe United Health (NYSE: UNH). Pfizer (NYSE: PFE) goes down to $32 ahead of the election, drops to $31.50, people think they made a lot of money, you buy Pfizer," said Cramer."This is what you do, I just gave it to you."Potential Winners Under Biden: Cramer last week discussed his "basket of winners" if presidential candidate Joe Biden were to win the election.He believes investors will go towards the solar industry. Two solar stocks he likes: First Solar (NASDAQ: FSLR) and Tesla (NASDAQ: TSLA).Cramer also thinks infrastructure will be a winner under Biden. Cramer likes these two infrastructure stocks: Caterpillar (NYSE: CAT) and Deere & Company (NYSE: DE).See more from Benzinga * Click here for options trades from Benzinga * 'Halftime Report's' Top Stocks To Watch: AGCO, Keysight And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Before you open a retirement account, you should know the disadvantages of Roth IRAs. Income limits are one drawback. Learn about the disadvantages of Roth IRAs.
Exxon guided investment sharply lower and warned of a massive possible writedown amid questions about its dividend. Chevron reported a surprise profit.
Vaccine specialist Moderna (MRNA) reported its fiscal Q3 2020 financial results Thursday morning. Let's run down the basic financial news first, and turn to the vaccine that everyone really wants to hear about: Q3 was kind of a weird quarter for Moderna from a financial perspective. On the one hand, an explosion in grant revenue tied to the COVID-19 pandemic sent revenues soaring 830% to $157.9 million. On the other hand, though, expenses soared as well -- up 166% to $393 million.And because $393 million is more than $157.9 million Moderna lost money.A lot of money.$0.59 per share to be precise -- 59% more than it lost in Q3 2019, before all the coronavirus business rolled in. What's more, that per-share loss would have been even higher, but for the fact that Moderna grew its share count 19%, dispersing its per-share losses over more shares outstanding overall.On the plus side, Moderna has raked in $1.2 billion in customer deposits so far this year for its mRNA-1273 coronavirus vaccine, and free cash is flowing in with $718.5 million. By the end of the quarter, Moderna had amassed a cash warchest bursting with $4 billion, and no debt to speak of.And now, the main event: Coronavirus.Moderna confirmed that it has fully enrolled its Phase 3 cllinical trial of mRNA-1273 with 30,000 patients participating.Initial data on mRNA-1273's effectiveness is "positive," said management, and the vaccine is proving to be "well-tolerated across all age groups and induc[ing] rapid and strong immune responses against SARS-CoV-2." The company is expecting to be able to release "1st interim" data on the trial in November if the vaccine proves to be at least 75% effective. In fact, at that level of effectiveness, a second round of data could arrive as early as December, or perhaps January.After participating in a conference call post-earnings, Needham analyst Alan Carr observed that there's a possibility the FDA could grant Moderna Emergency Use Authorization to begin distributing mRNA-1273 around this time -- December 2020. By that point, Moderna says it will have produced 20 million doses of the vaccine, which can immediately begin being distributed. Still, Carr thinks it prudent not to count on any revenues being recognized from mRNA-1273 sales this year, pushing that prospect off into 2021 instead -- but predicting sales will reach $2 billion in 2021.What does this mean for the stock? In Carr's opinion, notwithstanding how much revenue Moderna receives from mRNA-1273, or how quickly (or how profitably), "COVID-19 vaccine news [alone will suffice to] drive the stock into 2021," and even after that, the analyst sees "substantial long-term value in the stock," which he rates "buy" with a $94 price target. (To watch Carr's track record, click here)In contrast, J.P. Morgan analyst Cory Kasimov, despite agreeing basically line by line with Carr's analysis on the timeline -- and holding an $89 price target not that's not that much lower than Carr's -- says he still feels it's necessary to remain "cautious" on Moderna stock in the near term, and assigns the stock a rating of only "neutral." (To watch Kasimov's track record, click here)Where does the rest of the Street side on this vaccine maker? It appears mostly bullish, as TipRanks analytics demonstrate MRNA as a Buy. Out of 11 analysts tracked in the last 3 months, 9 are bullish on the stock while 1 remains sidelined and 1 is bearish. With a return potential of nearly 46%, the stock’s consensus target price stands at $98.60. (See MRNA stock analysis on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
GE’s stock jumped 4.5% the day of its strong earnings report, but still fell this past week. It has remained stuck in the same price range since the beginning of June. Is a secondary offering in the cards?
If there were any doubts left about whether the market would be "risk-on" or "risk-off" going into the election, Friday's selloff pretty much iced it. The toggle has switched to the off position.The late-week meltdown ignited after earnings from four of the five FAANGs that were mostly positive, but perhaps lacking in the guidance department (see more below). Combine that with the resurgence of COVID-19, the Senate adjourning with no more progress on a stimulus package, and the culmination of a long and contentious election season, and it's no wonder investors seem ready for a break. Even before FAANG earnings officially put things on ice, many investors showed signs of risk aversion ahead of the election. That made itself pretty clear with selloffs on Monday and Wednesday. Major indices suffered their worst week since March, and now people are openly making comparisons between this pre-election skid and the one we saw heading into the 2016 election.As noted this morning, keep an eye on futures Sunday night into Monday, and especially on Tuesday night as returns come in. Election night 2016 was a wild one for the futures market, featuring a steep plunge when it initially looked like results might be contested, followed by a meteoric rally when it became clear there'd be a victor without much fuss or muss.A wild ride could play out this time if things look testy by late Tuesday night. Or, if it looks relatively smooth, stocks could get a lift. It's arguably not so much who wins, but whether there's a chance of a long, drawn-out chaotic fight for a winner.Late Rally Back; A New Policy From The Fed A fierce recovery effort at the very end of Friday's session might put Monday's open into more solid territory. A late-breaking news item from the Fed about 40 minutes before the close also potentially contributed to the late rally. The Fed said it's reducing minimum loan sizes for smaller businesses that want to use the Fed's lending program. It's also easing restrictions on debt for companies already using the program. The Fed called these moves "two important ways to better target support to smaller businesses that employ millions of workers and are facing continued revenue shortfalls due to the pandemic."Basically, the Fed is trying to inject more money into the economy--something Congress and the White House haven't done with a stimulus since spring--which would possibly drive up economic growth expectations. The idea could be that this might help small businesses bridge the gap between now and any fiscal stimulus.Strong Data Raise Hopes For New Week There are other signs things might improve once the election excitement fades. Economic data have been solid lately. Gross domestic product (GDP) for Q3 came in above estimates yesterday, and initial jobless claims have finally started to ease a bit. New home sales for September were a bit subdued, but that's the only data all week that looked below average.The problem is that the good news is hitting a wall of worry centered on the election, COVID-19, and lack of a stimulus. Until we get those behind us (and it could be a while), risk premium in the market might continue unravelling as we saw this week. Technically, a lot of damage got done on the charts this week. The Dow Jones Industrial Average ($DJI) retested its 200-day moving average (before settling above it--see chart below) and the SPX took out its 50-day and 100-day moving averages. There appears to be potential technical support near the SPX 200-day moving average at around 3130, but that's still a long way down, so perhaps look for bulls to defend the psychological 3200 handle if things fall further.But if you're following corrections, the Nasdaq (COMP) has fallen 10% from its all-time high. The SPX is down 8.7% from its peak, so it's close but not all the way into correction territory.CHART OF THE AFTERNOON: MUSCLE MEMORY? The Dow Jones Industrial Average ($DJI-candlestick) retested its 200-day moving average (blue line) and closed above it. This is a level the index visited back in June and August (yellow circles), so it could be a pivotal level to watch, going forward. Data source: S&P Dow Jones Indices. Chart source: The thinkorswim® platform from TD Ameritrade. For illustrative purposes only. Past performance does not guarantee future results. Roadmap Left At Home As Guidance Lacking One thing besides the virus and election that some thought could potentially "catalyze"(is that a word?) Wall Street from its doldrums is earnings season, which is about half over. As usual, media headlines have zeroed in on the number of companies "beating" Wall Street's expectations. That stands at about 85% so far, but might not be the best way to judge. That's because analyst projections were so conservative this quarter that beating them is like your kid receiving a participation trophy. Investors are getting wise to this, too, as you can see this week from some companies like Microsoft Corporation (NASDAQ: MSFT) reporting a beat but getting punished because of weak guidance.Many companies, including Apple Inc. (NASDAQ: AAPL), are still holding out and declining to provide guidance. Some cite "uncertainty," though it's arguable that no quarter was ever "certain," even before COVID-19 came along. It's quite possible that this lack of guidance could be one factor keeping stocks from getting as much of a lift from earnings as normal.Among the major companies besides AAPL reporting recently but not sharing guidance are General Electric Company (NYSE: GE), Caterpillar Inc. (NYSE: CAT), 3M Co (NYSE: MMM), Xerox Holdings Corp (NYSE: XRX), Raytheon (RTN), and United Parcel Service, Inc. (NYSE: UPS). Knowing what happened last quarter but not getting forecasts for this quarter leaves investors hanging without a road map.One More Glance At FAANGs Earnings from the four reporting FAANGs looked good from a bottom and top-line standpoint, with no major misses. However, it appears that for all but one of the companies, Alphabet Inc (NASDAQ: GOOGL), the pre-earnings exuberance got carried away a bit.That's because it came down not to the top and bottom lines as much as to the stuff under the surface. With Facebook, Inc. (NASDAQ: FB), investors honed in on higher than expected spending levels in Q3. With AAPL, there was disappointment that iPhone sales missed Street expectations It's hard to find anything really unlikable about Amazon.com, Inc.'s (NASDAQ: AMZN) results, but that stock could be suffering a little profit-taking.The iPhone softness in AAPL's quarter as customers waited for the new 5G product might actually end up being a tailwind for AAPL going into its December and March quarters. That's because some of the people who'd previously waited to replace their phones might start doing that in the current quarter. So instead of pulling forward demand, as many Tech companies did early in the pandemic, AAPL kind of "pushed back" demand. Almost every S&P sector lost ground Friday as this disappointing week came to a close, but none got punished harder than Tech. It fell 2.1% on Friday and is down 2% over the last month. Investors might not be used to Tech being on the defensive this way, but considering the high value of that sector going into election season it's not all that surprising to see premiums coming out of there more than other sectors. One asset group that went against the grain Friday was the bond market. Pressure on Treasuries sent the 10-year yield to a new four-month high above 0.87%. Q3 GDP data might have given yields a lift, but it also could reflect the same sort of position-evening we saw in stocks today. People had been trending to the long side of the bond market this week, but didn't want to go into the weekend with that exposure.There was also a pretty muted reaction in the Cboe Volatility Index (VIX) today, as it didn't rise above the psychological 40 level. Maybe there's not as much concern around the election as people originally thought, or it could also reflect people exiting positions ahead of the weekend.Quick Look Ahead Next week features a heavy data calendar, with construction spending, October auto sales, factory orders, and--last but probably first in investors' hearts--the October payrolls report on Friday.From an earnings perspective, a lot of the fireworks are over, but there's no holiday next week. Reporting companies in coming days are expected to include PayPal Holdings Inc (NASDAQ: PYPL), Allstate Corp (NYSE: ALL), General Motors Company (NYSE: GM), Kohl's Corporation (NYSE: KSS), CVS Health Corp (NYSE: CVS), Marriott International Inc (NASDAQ: MAR), and Norwegian Cruise Line Holdings Ltd (NYSE: NCLH). Those last two could be important to watch for updates on travel demand as the U.S. and Europe fend with this new wave of virus cases.TD Ameritrade® commentary for educational purposes only. Member SIPC.Photo by Luca Bravo on UnsplashSee more from Benzinga * Click here for options trades from Benzinga * Apple Falls 4% As iPhone Sales Disappoint, But Most FAANG Results, Including Amazon's, Look Firm * FAANG Fans, On Your Marks: Apple, Amazon, Alphabet And Facebook Earnings Awaited After Close(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
”The more scale you have,” AMD CEO Lisa Su says, “the more you can do for your customers.” For investors, the picture is more complicated.
Amazon reported third-quarter revenue and earnings Thursday that came in well ahead of consensus estimates, and analysts remain bullish on the e-commerce stock going into the holiday quarter. Amazon Analysts On Prime, Sales Trends: Amazon.com Inc (NASDAQ: AMZN) had strong sales growth for several product categories including hard lines, consumables, soft lines and media, Raymond James analyst Aaron Kessler said in a note. Prime member engagement was strong, with members shopping more frequently and across more categories.Kessler has an Outperform on Amazon with a $3,500 price target.Needham analyst Laura Martin views Amazon as "the catalyst for an earlier holiday shopping season this year, starting with Prime Day on Oct 13-14th."Martin, who has a Buy rating on Amazon with a $3,700 price target, said the fourth quarter is off to a strong start, with third-party sellers seeing 60% higher sales year-over-year for the two days of Prime Day.Amazon Adverting Takeaways: The advertising segment for Amazon is represented in its "other" segment and was a highlight in many analyst updates Friday. "Ad revenue grew to nearly $5B in 3Q20, suggesting AMZN is hiding a business worth about $500B in the public markets in its other sales line," said Martin.KeyBanc analyst Edward Yruma called advertising a "key driver of profitability" for Amazon."Amazon has turned that traffic (AWS) into valuable real estate for advertisers, and in turn, had strong advertising performance in 3Q," the analyst said. Related Link: Jim Cramer On Big Tech Earnings, Why He Likes AlphabetView more earnings on AMZNAnalysts On AWS: AWS customer usage was strong and Amazon saw "companies meaningfully growing their plans to move to AWS," y Kessler said. KeyBanc's Yruma said year-over-year AWS growth in absolute dollars "was the largest the company has seen, and operating margin expanded by over 500 bps." Amazon's Valuation: Amazon has "several hidden value multipliers that suggest it is worth between $4,500 and $5,000 a share," Martin said. The company has $600 billion of media asset value, the analyst said. "We believe that services segment revenue and margins (including advertising and subscription) are growing faster than Amazon's ecommerce assets, which implies valuation multiple expansion over time."Yruma has a $3,500 price target on Amazon and breaks it down as follows: $1,200 for North American retail (excluding advertising), $525 for international retail (excluding advertising), $1,275 for AWS and $480 for advertising.What's Next: Emarketer estimates online sales in the U.S. will grow 32% in 2020.Amazon will be a "market share gainer within a growing pie," Martin said. "Amazon has an outstanding 15-year track record of turning its growth investments into new businesses with high ROIs, such as AWS and advertising."AMZN Price Action: Amazon shares lost 5.45% in Friday's session, closing at $3,036.15.Photo courtesy of Amazon. Latest Ratings for AMZN DateFirmActionFromTo Oct 2020BenchmarkMaintainsBuy Oct 2020Piper SandlerMaintainsOverweight Oct 2020Credit SuisseMaintainsOutperform View More Analyst Ratings for AMZN View the Latest Analyst RatingsSee more from Benzinga * Click here for options trades from Benzinga * Jim Cramer On Big Tech Earnings, Why He Likes Alphabet * Amazon's .1B Revenue, .37 EPS Shatter Estimates In Strong Q3(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Nearly a year into a global pandemic the world is still on the back of its heels. In the face of ever increasing infection rates, world economies have slowed rapidly and unemployment has increased significantly, and now governments are reconsidering shutting down entire countries once again. At the same time, the federal government has failed to pass a second stimulus package to prop up individuals who have lost their jobs and may be facing homelessness, as well as the need to help state and local governments provide a backstop against their own losses.Given this backdrop, there is a lot riding on a potential vaccine and/or cure for COVID-19. There are many approaches that a lengthy list of varying companies are taking to bring their respective product to market.Any company that does successfully bring a product to market that helps in the fight against the virus may see a significant increase in revenues as well as an in-kind increase in profits. B. Riley Securities has highlighted three biotech companies that are approaching the virus from different directions. We ran the trio through TipRanks’ database to see how B. Riley's recent analysis compared to other analysts’ projections.Altimmune Inc. (ALT)Altimmune is a biopharmaceutical company that develops vaccines and immune modulating therapies. Fighting the virus is likely to need both approaches, a vaccine as well as an immune therapy. With this kind of focus, Altimmune’s fortunes changed quickly with the onset of the COVID pandemic.Altimmune produces AdCovid, a single dose, intranasal vaccine to protect against COVID-19. As B. Riley analyst Mayank Mamtani points out, Altimmune’s products “stands out in regards to lung specific IgA and CD8+ T-Cell responses” and further states that “In our view it blocks the virus at the source within the nose and respiratory tract." AdCovid’s preclinical data shows a great deal of promise.ALT stock was trading around $2 per share back in January. Once the company got involved in the fight against COVID-19, the stock jumped up to a high of $33.00 per share, but is now trading at $11; still, this is a move of +450% year-to-date. Given what Altimmune has going for it, and the potential upside, this prompted Mamtani to give Altimmune a Buy rating in his recent analysis. The analyst has a price target of $31, suggesting a potential upside of 182% from current levels. (To watch Mamtani’s track record, click here).As it turns out, there are 4 Buy ratings equating to a Strong Buy on ALT with a low price target of $31 (coming from B. Riley), an average Price target of $49 and a high price target of $80. The average Price Target equates to a potential upside move of 345%. (See ALT stock analysis on TipRanks)Arcturus Therapeutics (ARCT)Arcturus Therapeutics focuses on RNA medicines with a focus on respiratory diseases. COVID, as it may be, is a virus that attacks the respiratory system. Arcturus has a proprietary LNP delivery system that enables a safer, more deliverable method of bioavailable therapy. Regarding this method and Arcturus’ product advancements to this, B. Riley's Mayank Mamtani noted, “Along with the proprietary LNP delivery platform, rapidly biodegradable LUNAR, alongside self-transcribing and replicating mRNA (STARR) technology, implies significant safety and durability advantage."Arcturus has a strong collaboration with Duke University and the Singapore Economic Development Corp to develop LUNAR-Cov19 (ARCT-021) -- a self-replicating mRNA vaccine the might be sufficient to address the Coronavirus outbreak. The potential COVID-19 vaccine is now in a Phase 1/2 trial, and upcoming clinical results are expected in 4Q20. Given the backing and the product development, there appears to be significant potential with this product.ARCT stock started the year at $10 per share but since has jumped to today’s price of $53 this is a 430% year-to-date increase.Considering the potential for the drug making it to market, Mamtani gives ARCT a Buy rating along with an $82 price target. This equates to an upside potential of 52% from current levels.Overall, what does the street have to say about ARCT? There are a total of 6 Buy ratings and all add up to a Strong Buy consensus rating. With an average price target of $75.17, the stock is expected to rise nearly 39% over the next months. (See ARCT stock analysis on TipRanks)Heat Biologics Inc (HTBX)Heat Biologics is a biopharmaceutical that develops immunotherapies. In development is a T-Cell activation platform that is proprietary and is a strong contender in the fight against COVID-19.There are similarities to SARS-Cov-1 from 2003 and today’s COVID-19. As it turns out, and as bad as it sounds, having previously contracted the original SARS-Cov-1 in 2003 would have been a good thing. Patients that recovered from the original SARS-Cov-1 and contracted the current COVID-19, are seeing long-lasting T-Cells memory and are generally asymptomatic or have mild symptoms. Given this, Heat Biologics is using an approach to mimics the original SARS-Cov-1 to provide immunity against COVID-19.Heat Biologics is in collaboration with Waisman Biomanufacturing to manufacture COVID-19 and are preparing to deliver its products to market. As B. Riley's Mamtani points out in his recent analysis, “we view single-dose format of gp96-IgG to serve as complementary to advanced C-19 vaccine candidates in developing combination-based approaches aimed at enhancing T cell immunity."Given the potential of the immunotherapies and T-Cell activation Platform and the partnership with Waisman Biomanufacturing, this prompted Mamtani to place, once again, a Buy rating on Heat Biologics shares. The analyst suggests that if everything goes as planned, HTBX will be a $4 stock in the next 12 months, implying nearly 245% return.As for other Wall Street analysts, there is only one additional rating on HTBX, which is also bullish. The average price target among the two stands at $4.50, which suggests a potential upside of a whopping 288%. (See HTBX stock analysis on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.